Melanoma-associated antigen 1 peptide presented by Human Leukocyte Antigen A*02:01 (MAGE-A1/HLA-A*02:01)

The MAGEA1-derived peptide presented by HLA-A*02:01 is a tumor-specific antigen complex that serves as a critical target for advanced cancer immunotherapies. MAGEA1 (Melanoma-associated antigen 1) is a member of the cancer-testis antigen family, which is typically expressed only in male germ cells and the placenta—tissues that do not express MHC Class I molecules. In various malignancies, MAGEA1 is aberrantly re-expressed, and its intracellular processing leads to the presentation of specific peptides, such as KVLEYVIKV, on the cell surface via the HLA-A*02:01 molecule [1][3]. Because HLA-A*02:01 is one of the most common MHC alleles in human populations, this complex is a highly attractive target for T-cell receptor (TCR) engineered therapies [4]. These therapies aim to exploit the high tumor specificity of MAGEA1 to induce potent cytotoxic T-lymphocyte responses while minimizing damage to normal somatic tissues [2]. Current clinical development focuses on optimizing TCR affinity to ensure robust anti-tumor activity and safety against potential cross-reactive epitopes.

Other names

MAGE-A1/HLA-A2 complexMAGE-A1 peptide-MHC complexMAGE-A1 pMHCMelanoma antigen family A 1 peptide-HLA-A*02:01 complex

Therapeutic agents, such as TCR-engineered T-cells, specifically bind to the MAGE-A1 peptide presented within the groove of the HLA-A*02:01 molecule on the surface of tumor cells. This binding event triggers T-cell activation, leading to the release of perforins and granzymes, which induce apoptosis and selective lysis of the target cancer cell.